Research Papers:

Effect of wound fluid on chemotherapy sensitivity of T24 bladder cancer cells with different enhancer of zeste homolog 2 status

Huan Bi, Zetian Zhang, Li Guo and Cheng Fu _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:63258-63264. https://doi.org/10.18632/oncotarget.18791

Metrics: PDF 1137 views  |   HTML 1883 views  |   ?  


Huan Bi1, Zetian Zhang2, Li Guo2 and Cheng Fu1

1Department of Urology Surgery, Liaoning Cancer Hospital and Institute, Shenyang 110042, China

2Department of Technology, Shenyang Yike Biotechnology Co., Ltd, Shenyang 110000, China

Correspondence to:

Cheng Fu, email: [email protected]

Keywords: bladder cancer, EZH2, wound fluid, chemotherapy, drug resistance

Received: May 04, 2017     Accepted: May 23, 2017     Published: June 28, 2017


The present study investigated the effect of zeste homolog 2 (EZH2) and wound fluid (WF) on chemotherapy sensitivities of T24 bladder cancer cells by using a collagen gel droplet embedded culture-drug sensitivity test (CD-DST). T24 bladder cancer cells with different EZH2 expression levels were co-cultured with postoperative WF from patients with bladder cancer. The CD-DST was performed to detect the sensitivity of tumor cells to gemcitabine and cis-diamminedichloridoplatinum (II) (cisplatin, DDP). The survival rates of the bladder cancer cells were used to determine the drug’s chemotherapeutic effect. EZH2 knockdown increased the sensitivity of the cells to gemcitabine and DDP, whereas EZH2 overexpression decreased the chemotherapeutic sensitivity. Except for the situation of EZH2 overexpression, co-culturing with WF induced significantly higher drug resistance in tumor cells. Overexpression of EZH2 and surgery-induced WF promoted the drug resistance of bladder cancer cells to the investigated chemotherapeutic agents, suggesting that more studies are needed to investigate the key mechanisms underlying the EZH2- and WF-induced reduction of susceptibility to chemotherapy drugs.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18791